<SEC-DOCUMENT>0001390478-22-000013.txt : 20220512
<SEC-HEADER>0001390478-22-000013.hdr.sgml : 20220512
<ACCEPTANCE-DATETIME>20220512161615
ACCESSION NUMBER:		0001390478-22-000013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220512
DATE AS OF CHANGE:		20220512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		22918011

	BUSINESS ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		6462005278

	MAIL ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sls-20220512.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:01fbedfe-32d7-4551-914c-778d96ce49ee,g:2f75c32d-5a3b-49d5-9611-ebdbd70aa4cd,d:e55ecbf21f1a4bcaaf754b0c14371c1e--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sls-20220512</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV80L2ZyYWc6MzNmMzBkM2EzYWVhNDI4NWJhMGY0MGYzNWE0MTUyYjgvdGFibGU6NTYyMGUxYjc2ZGM2NGQ4NWI2MWQ4MzZhNWY5MDVjN2YvdGFibGVyYW5nZTo1NjIwZTFiNzZkYzY0ZDg1YjYxZDgzNmE1ZjkwNWM3Zl8xLTEtMS0xLTMwMTU4_f9daaec0-2d57-422d-a890-42972fa7501c">0001390478</ix:nonNumeric><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV80L2ZyYWc6MzNmMzBkM2EzYWVhNDI4NWJhMGY0MGYzNWE0MTUyYjgvdGFibGU6NTYyMGUxYjc2ZGM2NGQ4NWI2MWQ4MzZhNWY5MDVjN2YvdGFibGVyYW5nZTo1NjIwZTFiNzZkYzY0ZDg1YjYxZDgzNmE1ZjkwNWM3Zl8yLTEtMS0xLTMwMTU4_a483b9e8-32b5-4cf8-94b4-48bfb86ecc51">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sls-20220512.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie55ecbf21f1a4bcaaf754b0c14371c1e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">UNITED STATES <br/>SECURITIES AND EXCHANGE COMMISSION  <br/>WASHINGTON, D.C. 20549 </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODI2_b82c617a-2e6b-41c9-beb6-4024a84e0fa6">8-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CURRENT REPORT<br/>PURSUANT TO SECTION 13 OR 15(d) OF THE <br/>SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yMzQ_296faab1-61f5-41a4-ad79-4260f26be6b6">May 12, 2022</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODIx_dcee7500-3a05-47ae-bc2a-cb2b2785a1f2">SELLAS Life Sciences Group, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8wLTAtMS0xLTMwMTU4_b9dd6d56-03e7-4f9f-b673-7467f4708129">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8wLTItMS0xLTMwMTU4_e02c6b9d-edaf-43a4-be99-369c7d39c16a">001-33958</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8wLTQtMS0xLTMwMTU4_19c329ac-c709-4c98-81f9-8db96d4b7591">20-8099512</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfNQ_c3468f99-a0e4-453b-9a8d-a6af31ae37cc">7 Times Square</ix:nonNumeric>, <ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfOQ_d8c82c25-19ef-4050-a0df-3aae307d0b59">Suite 2503</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfMTI_e81610b6-8df5-44b5-94f5-46cf3dff35b1">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfMTY_eda30194-41dd-4581-9c04-2a84a8227a7d">NY</ix:nonNumeric> <ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfMTk_938754e0-151e-40df-bf13-d71cfc5aeb35">10036</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV82LTAtMS0xLTMwMTU4L3RleHRyZWdpb246N2I0YzZlOTY3ZWE4NDRmNTk5NzQwNWQzMmFiOTM2OTNfNTY_9e2c4fe7-9b6d-4b72-8470-a2dc0a2f8b9d">(646)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV82LTAtMS0xLTMwMTU4L3RleHRyZWdpb246N2I0YzZlOTY3ZWE4NDRmNTk5NzQwNWQzMmFiOTM2OTNfNTk_aa1e7a1e-ddaa-42eb-90f1-a7f1965c379f">200-5278</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODI4_3f1d0625-09fa-47e5-9597-bb2bc0659ab5">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR&#160;230.425) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODIy_177d571a-fe33-4210-8993-4eb68db46559">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR&#160;240.14a-12) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODI0_a7b51c9c-b898-4ea8-b497-0d1c83af7e93">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR&#160;240.14d-2(b)) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODI1_0499c772-d303-4c1c-9f03-130700c51d15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR&#160;240.13e-4(c)) </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NGQ5ZTA5Y2FiMjAyNDc2MWJlYThkMmY1MDM4YzM5Y2UvdGFibGVyYW5nZTo0ZDllMDljYWIyMDI0NzYxYmVhOGQyZjUwMzhjMzljZV8xLTAtMS0xLTMwMTU4_b104ed90-c4af-4fe7-bdaf-dedbce47e5e8">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NGQ5ZTA5Y2FiMjAyNDc2MWJlYThkMmY1MDM4YzM5Y2UvdGFibGVyYW5nZTo0ZDllMDljYWIyMDI0NzYxYmVhOGQyZjUwMzhjMzljZV8xLTEtMS0xLTMwMTU4_a3912d91-526f-4145-9ab9-5508ac2ae002">SLS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NGQ5ZTA5Y2FiMjAyNDc2MWJlYThkMmY1MDM4YzM5Y2UvdGFibGVyYW5nZTo0ZDllMDljYWIyMDI0NzYxYmVhOGQyZjUwMzhjMzljZV8xLTItMS0xLTMwMTU4_748a4acc-677c-4b5a-8111-c3cf82033333">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter). </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODMx_8254a9c0-ada0-4457-a8a4-70389b7bf847">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744; </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2022, SELLAS Life Sciences Group, Inc. (&#8220;SELLAS&#8221;) issued a press release (the &#8220;Press Release&#8221;) announcing its financial results for the quarter ended March 31, 2022 and providing a corporate update.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form&#160;8-K&#160;shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form&#160;8-K shall not be incorporated by reference into any filing with the SEC made by SELLAS whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls-202205128xkexhibit991.htm">Press Release dated May 12, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELLAS Life Sciences Group, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sls-202205128xkexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2849f49610e54479848dea81903b10e5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:112%">SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update</font></div><div><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:11.89pt">Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor    &#8211;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:11.89pt">$25 Million of Gross Proceeds from Capital Raise in April 2022 and $1 Million Milestone Payment Received in May 2022 Add to Cash Balance of $14.3 Million as of March 31, 2022    &#8211;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NEW YORK, May 12, 2022 &#8211; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS Life Sciences Group, Inc.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(NASDAQ&#58; SLS) (&#8220;SELLAS&#8221; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;SELLAS achieved several key milestones in the first four months of 2022, including expanding our development pipeline and strengthening our balance sheet,&#8221; said Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer of SELLAS. &#8220;We entered into an exclusive license agreement with GenFleet Therapeutics (Shanghai), Inc. (&#8220;GenFleet&#8221;) granting us exclusive rights for the development and commercialization of GFH009, a highly selective and potentially first and best in class small molecule cyclin-dependent kinase 9 (&#8220;CDK9&#8221;) inhibitor, across all therapeutic and diagnostic uses worldwide outside of Greater China. We believe that GFH009 is a complementary strategic fit to our overall clinical development plans and provides us with an opportunity to further advance into the market for acute myeloid leukemia (&#8220;AML&#8221;) therapeutics. GFH009 affords us the potential to treat active AML disease while our lead clinical candidate, galinpepimut-S (GPS), is potentially used in the maintenance setting in AML. The in-license of GFH009 also provides us an opportunity to address a very important pediatric market of soft tissue sarcomas as well as other cancers.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dr. Stergiou added, &#8220;During the first quarter, we continued to advance the Phase 3 REGAL trial for our lead asset, GPS and, in April, we also launched an expanded access program for GPS in response to multiple requests from physicians with which we hope to potentially improve clinical outcomes for patients and their families. Subsequent to the quarter, we fortified SELLAS&#8217; balance sheet with the closing of a public offering with gross proceeds of $25 million. The funds position us to advance our clinical programs for both GPS and GFH009. We are pleased by the progress we made over the first quarter of 2022 and remain steadfast in our mission to develop innovative treatments and improve the standard of care available to patients. With GPS and GFH009, we now have two significant clinical assets in our pipeline, with several opportunities to develop and potentially commercialize, cancer drugs that can prolong the lives of patients battling cancer.&#8221;  </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Pipeline Updates&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Galinpepimut-S (GPS)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">Expanded Access Program&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In April 2022, the Company launched a pre-approval access&#47;expanded access program (&#8220;EAP&#8221;) with SELLAS&#8217; lead asset, GPS, for treating patients suffering from AML. For more information on the GPS EAP, please visit the PIPELINE page at </font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">www.sellaslifesciences.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">Phase 3 REGAL Study&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SELLAS continued to progress enrollment of patients and activation of additional sites in the United States, Europe, and Asia in the first quarter of 2022. The Company believes that enrollment for the REGAL study will be completed in late 2022 or early in the first quarter of 2023 and the planned interim analysis will occur by the end of the first half of 2023, provided that its statistical assumptions and assumptions regarding the impact of COVID-19 on the operations of clinical sites as well as the duration of the pandemic remain unchanged. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">Phase 1&#47;2 GPS Study in Combination with Merck&#8217;s KEYTRUDA&#174;&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In February 2022, the Company completed enrollment in the Phase 1&#47;2 clinical trial of GPS in combination with Merck&#8217;s anti-PD-1 therapy, KEYTRUDA&#174; (pembrolizumab), in second or third line Wilms Tumor-1 (WT1+) relapsed or refractory metastatic ovarian cancer. Data from 15 patients is currently being reviewed by SELLAS and Merck, with top-line results expected by mid-2022 and a final data analysis for all evaluable patients expected by the end of 2022.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">Phase I GPS Study in China&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In March 2022, an IND application to initiate the first clinical trial in China for GPS was approved by China&#8217;s National Medical Products Administration (&#8220;NMPA&#8221;), which triggered a milestone payment of $1 million received by the Company in May 2022.  The IND, for a small Phase 1 clinical trial investigating safety, was submitted by SELLAS&#8217; partner in China, 3D Medicines Inc. (&#8220;3D Medicines&#8221;), with 3D Medicines expecting to initiate the trial by mid-2022. 3D Medicines&#8217; current clinical development plan provides for initiation of a Phase 2 clinical trial following receipt of satisfactory safety data from the Phase 1 clinical trial&#59; the initiation of the Phase 2 clinical trial will also trigger a milestone payment to SELLAS. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">New Patent Allowance&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In February 2022, the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering certain WT1-targeting peptides, in combination with other molecules such as other peptides and immunomodulating compounds, useful for treatment of WT1-expressing cancers. The patent application covers WT1-targeting peptides linked to other molecules and is expected to be granted later this year. The patent will have a term extending to at least 2026. This patent complements the Company&#8217;s existing composition of matter patents covering GPS peptides which expire in 2033 not including any potential extensions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">GFH009</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">In-License&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> On March 31, 2022 the Company announced it had entered into an exclusive license agreement with GenFleet Therapeutics (Shanghai), Inc. (&#8220;GenFleet&#8221;), that grants rights to SELLAS for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, across all therapeutic and diagnostic uses worldwide outside of Greater China (mainland China, Hong Kong, Macau and Taiwan). CDK9 activity has shown a negative correlation with overall survival in a number of cancer types, including hematologic cancers, such as AML and lymphomas, as well as solid cancers, such as osteosarcoma, pediatric soft tissue sarcomas, and melanoma, and endometrial, lung, prostate, breast and ovarian cancer.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Ongoing Phase 1 Clinical Trial&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In April 2022, SELLAS announced that initial data from the first four dose levels of the ongoing Phase 1 dose-escalating clinical trial of GFH009 show a significant anti-leukemic effect at the 9mg and 15mg dose levels given twice a week in AML patients resistant to standard-of-care treatments, with two patients </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">refractory to, or relapsed after, venetoclax treatment experiencing greater or equal to a 50 percent decrease in bone marrow blasts following GFH009 monotherapy. </font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">There have been no dose-limiting toxicities, including no grade 3&#47;4 neutropenia (an abnormally low count of a type of white blood cells), in the first four dose levels (2.5mg, 4.5mg, 9mg and 15 mg) with the twice-weekly GFH009 dosing. The first AML patient has been enrolled in the fifth dose level (22.5mg twice a week) cohort.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The last planned dose level in this clinical trial is 30mg.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Corporate Highlights&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">Underwritten Public Offering&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">On April 5, 2022, the Company consummated an underwritten public offering providing gross proceeds to the Company of $25.0 million, before deducting underwriting discounts and commissions and offering expenses.  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">Bolstered Leadership Team&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In March 2022, SELLAS appointed Robert Francomano as Chief Commercial Officer. In January 2022, the Company promoted John Burns to Senior Vice President, Finance, and Chief Accounting Officer. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">Settlement of Legacy Galena Litigations&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In February 2022, SELLAS received the final court approval of the settlement of securities litigation relating to the Company&#8217;s predecessor, Galena. This marked the end to all litigation related to activities of Galena.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Financial Results for the First Quarter 2022&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Licensing revenue&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Licensing revenue for the first quarter of 2022 was $1.0 million, as compared to $5.7 million for the same period in 2021. Licensing revenue in the first quarter of 2022 was related to China&#8217;s NMPA approval of an IND application by 3D Medicines and licensing revenue during the first quarter of 2021 was related to the initial transaction price of the license agreement with 3D Medicines, which was recognized over a period of time. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">R&#38;D Expenses&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Research and development expenses for the first quarter of 2022 were $4.6 million, as compared to $4.3 million for the same period in 2021. The increase was primarily due to an increase in clinical trial expenses for the ongoing Phase 3 clinical trial of GPS in AML and personnel related expenses due to increased headcount, partially offset by a decrease in manufacturing expenses due to the timing of the manufacture of registration batches of GPS in the prior year.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Acquired In-Process Research and Development&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Acquired in-process research and development for the first quarter 2022 was $10.0 million, related to the in-licensing of GFH009. There was no acquired in-process research and development during the first quarter of 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">G&#38;A Expenses&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">General and administrative expenses for the first quarter of 2022 were $3.0 million, as compared to $3.6 million for the same period in 2022. The decrease was primarily due to a decrease in amortization expense associated with the capitalized contract acquisition costs of the 3D Medicines license agreement and a decrease in professional service fees, partially offset by an increase in personnel related expenses due to increased headcount. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Net Loss&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Net loss was $16.7 million for the first quarter of 2022, or a basic and diluted loss per share of $1.05, as compared to a net loss of $2.4 million for the same period in 2021, or a basic and diluted loss per share of $0.16. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cash Position&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> As of March 31, 2022, cash and cash equivalents totaled approximately $14.3 million. Subsequent to March 31, 2022, the Company consummated an underwritten public offering providing gross proceeds to the Company of $25.0 million, before deducting underwriting discounts and commissions and offering expenses, and received a $1.0 million milestone payment from 3D Medicines.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About SELLAS Life Sciences Group, Inc.</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS Life Sciences Group, Inc. (NASDAQ&#58; SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS&#8217; lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For more information on SELLAS, please visit </font><font style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.sellaslifesciences.com</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">This press release contains forward-looking statements. All statements other than statements of historical facts are &#8220;forward-looking statements,&#8221; including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;intend,&#8221; or &#8220;continue&#8221; and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS and GFH009 for various cancer indications,  including the timing of commencement and completion of clinical trials therefor, the potential for GPS and GFH009 as drug development candidates for various cancer indications, alone and in combination with other therapeutic agents, the timing for the completion of enrollment for the GPS REGAL Phase 3 clinical trial, the timing for analyses and reporting of data for GPS, the potential for regulatory approval and commercialization of GPS, and the potential for additional milestone payments under the license agreement with 3D Medicines. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company&#8217;s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption &#8220;Risk Factors&#8221; in SELLAS&#8217; Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS&#8217; forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Investor Contact</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Allison Soss</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">KCSA Strategic Communications</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Email&#58; </font><font style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS&#64;kcsa.com</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Phone&#58; 212.896.1267</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Media Contact</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Raquel Cona &#47; Michaela Fawcett</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">KCSA Strategic Communications</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Email&#58; </font><font style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS&#64;kcsa.com</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Phone&#58; 212.896.1276</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,700&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of licensing revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,611&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,284&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,024&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,561&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,735&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,945&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,735)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,245)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-operating income (expense)&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,744)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,403)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Per share information&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.05)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,897,479&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,877,317&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.766%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,252&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,355&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,487&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,589&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,839&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,044&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,127&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits and other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,434&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,275&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,842&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,144&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,012&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,679&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,982&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development payable, non-current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">883&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,409&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,928&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.0001 par value&#59; 5,000,000 shares authorized&#59; Series A convertible preferred stock, 17,500 shares designated&#59; no shares issued and outstanding at March 31, 2022 and December 31, 2021</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Common stock, $0.0001 par value&#59; 350,000,000 shares authorized, 15,905,999 and 15,895,637 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,370&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,948&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155,347)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138,603)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,025&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,347&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,434&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,275&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sls-20220512.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:01fbedfe-32d7-4551-914c-778d96ce49ee,g:2f75c32d-5a3b-49d5-9611-ebdbd70aa4cd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sls="http://www.sellaslifesciences.com/20220512" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sellaslifesciences.com/20220512">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20220512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20220512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sellaslifesciences.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sls-20220512_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:01fbedfe-32d7-4551-914c-778d96ce49ee,g:2f75c32d-5a3b-49d5-9611-ebdbd70aa4cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_953c00f3-4127-42ac-94ff-c63e6132ba60_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_94f016e2-2557-4386-8377-76efdf1c1f10_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bbbfa742-ae15-49b4-b5e5-31eb3b7ff6e1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e3b542d7-7c93-4524-8cac-7899e40512d4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cdf72841-365c-452f-8f4c-2cd7f66736dc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1d097a3b-2ac6-4455-ac66-6dfac75a33f0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_921cce7d-ad71-4a21-8a01-2346d0236786_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_8585cc55-97d5-4e77-aee4-b3f611e77c30_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_92d5f5af-b00d-4276-9d6d-b81deafa603d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4ecbe87f-e3b8-49c0-aa6b-da4416780177_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8e920a9f-6389-431e-a654-ab58cbdd94bf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_2e9a3d43-7914-4410-b137-226f79884c06_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_227abfbf-490d-4795-93cb-06a54f477af4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ad6fe4ec-f6be-400f-8b1f-5ed8fda683aa_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5fd128a6-c9c6-4d2a-ab75-6f4d35e653b5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f610d437-cdc2-4b28-a4ff-98889addc9cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3bca4db7-9ca1-45ff-b0dc-d0128212d7e2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_896ff6ef-ff2d-4016-8588-1e9644ca3c91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ebdf5f41-1caf-43c9-b53e-619f58463834_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ae54ab56-45d7-4f47-9dd5-4509fa6e9cad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_32038229-6053-403c-b3d2-cdbeb53bcb2c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3c10495c-ac81-4b5b-b072-804b95da76a2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c16e54d6-ba97-4eeb-bf94-d83c5bc0178d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sls-20220512_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:01fbedfe-32d7-4551-914c-778d96ce49ee,g:2f75c32d-5a3b-49d5-9611-ebdbd70aa4cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sellaslifesciences.com/role/Cover" xlink:type="simple" xlink:href="sls-20220512.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sellaslifesciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_77fa0f6b-74db-4df4-a1f5-f7fba7b7b3a0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_DocumentType_77fa0f6b-74db-4df4-a1f5-f7fba7b7b3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c027c7a8-5442-46ae-bb0d-dacd36cecbb5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_DocumentPeriodEndDate_c027c7a8-5442-46ae-bb0d-dacd36cecbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_caa76383-3e66-49a3-b7e6-90ce97543f0e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityRegistrantName_caa76383-3e66-49a3-b7e6-90ce97543f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c02f8655-1304-4699-9dc5-0e1dff4e8707" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c02f8655-1304-4699-9dc5-0e1dff4e8707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_281bf556-b1ba-4031-b358-c200bdeca4e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityFileNumber_281bf556-b1ba-4031-b358-c200bdeca4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_173397a5-09eb-4336-b896-c006ce5184bd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityTaxIdentificationNumber_173397a5-09eb-4336-b896-c006ce5184bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0d71267d-f963-45d0-a5c1-7c4d86f5370e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityAddressAddressLine1_0d71267d-f963-45d0-a5c1-7c4d86f5370e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_033d56ed-9a44-46fe-b6b9-33d0e0d2f411" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityAddressAddressLine2_033d56ed-9a44-46fe-b6b9-33d0e0d2f411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e4ab9de3-82e3-4c3b-9fc5-55c1ff5a359b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityAddressCityOrTown_e4ab9de3-82e3-4c3b-9fc5-55c1ff5a359b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_226a9693-1892-4564-a420-5b3733bf2b34" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityAddressStateOrProvince_226a9693-1892-4564-a420-5b3733bf2b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7451c46a-6150-4337-8a5c-c97ceb08e699" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityAddressPostalZipCode_7451c46a-6150-4337-8a5c-c97ceb08e699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_92ccf223-da9f-4c5e-af88-3f7d902d3f5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_CityAreaCode_92ccf223-da9f-4c5e-af88-3f7d902d3f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9f91db6c-18cf-48c3-8ba5-b869aa6be196" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_LocalPhoneNumber_9f91db6c-18cf-48c3-8ba5-b869aa6be196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_3695224c-2ecd-4c67-9f99-325b8538842e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_WrittenCommunications_3695224c-2ecd-4c67-9f99-325b8538842e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3a1e2f7c-5cff-4374-ad83-4cfe0b1e7511" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_SolicitingMaterial_3a1e2f7c-5cff-4374-ad83-4cfe0b1e7511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_9a3a8f3f-0225-4a0d-bbd1-3b7b51f4fdf7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_PreCommencementTenderOffer_9a3a8f3f-0225-4a0d-bbd1-3b7b51f4fdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019f890b-0677-4846-8b88-9f91713fbf4d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019f890b-0677-4846-8b88-9f91713fbf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5fc04a8f-779f-4fca-bdc8-648cd14c471f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_Security12bTitle_5fc04a8f-779f-4fca-bdc8-648cd14c471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c930069f-b39b-4906-930b-d632045a52e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_TradingSymbol_c930069f-b39b-4906-930b-d632045a52e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_393cf503-620c-4cd8-b1df-1e2d585ffc26" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_SecurityExchangeName_393cf503-620c-4cd8-b1df-1e2d585ffc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ec503ffc-ff9a-4e89-90bb-94311ae48f7f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityEmergingGrowthCompany_ec503ffc-ff9a-4e89-90bb-94311ae48f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4e7f2358-6bcc-405c-bf81-31b313d99a1c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_EntityCentralIndexKey_4e7f2358-6bcc-405c-bf81-31b313d99a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_de44981a-58c4-406d-98dc-f8c33e2ea8b1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab207839-15c0-4a30-8311-b401f53e361b" xlink:to="loc_dei_AmendmentFlag_de44981a-58c4-406d-98dc-f8c33e2ea8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140412538554408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS Life Sciences Group, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8099512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Times Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">200-5278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>sls-20220512_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sls-20220512.xsd" xlink:type="simple"/>
    <context id="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV80L2ZyYWc6MzNmMzBkM2EzYWVhNDI4NWJhMGY0MGYzNWE0MTUyYjgvdGFibGU6NTYyMGUxYjc2ZGM2NGQ4NWI2MWQ4MzZhNWY5MDVjN2YvdGFibGVyYW5nZTo1NjIwZTFiNzZkYzY0ZDg1YjYxZDgzNmE1ZjkwNWM3Zl8xLTEtMS0xLTMwMTU4_f9daaec0-2d57-422d-a890-42972fa7501c">0001390478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV80L2ZyYWc6MzNmMzBkM2EzYWVhNDI4NWJhMGY0MGYzNWE0MTUyYjgvdGFibGU6NTYyMGUxYjc2ZGM2NGQ4NWI2MWQ4MzZhNWY5MDVjN2YvdGFibGVyYW5nZTo1NjIwZTFiNzZkYzY0ZDg1YjYxZDgzNmE1ZjkwNWM3Zl8yLTEtMS0xLTMwMTU4_a483b9e8-32b5-4cf8-94b4-48bfb86ecc51">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODI2_b82c617a-2e6b-41c9-beb6-4024a84e0fa6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yMzQ_296faab1-61f5-41a4-ad79-4260f26be6b6">2022-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODIx_dcee7500-3a05-47ae-bc2a-cb2b2785a1f2">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8wLTAtMS0xLTMwMTU4_b9dd6d56-03e7-4f9f-b673-7467f4708129">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8wLTItMS0xLTMwMTU4_e02c6b9d-edaf-43a4-be99-369c7d39c16a">001-33958</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8wLTQtMS0xLTMwMTU4_19c329ac-c709-4c98-81f9-8db96d4b7591">20-8099512</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfNQ_c3468f99-a0e4-453b-9a8d-a6af31ae37cc">7 Times Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfOQ_d8c82c25-19ef-4050-a0df-3aae307d0b59">Suite 2503</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfMTI_e81610b6-8df5-44b5-94f5-46cf3dff35b1">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfMTY_eda30194-41dd-4581-9c04-2a84a8227a7d">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV8zLTItMS0xLTMwMTU4L3RleHRyZWdpb246MDU3ZDlhNjgyNGIyNDNlOGE1MDI1YjdiNjgxZTM5ZmVfMTk_938754e0-151e-40df-bf13-d71cfc5aeb35">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV82LTAtMS0xLTMwMTU4L3RleHRyZWdpb246N2I0YzZlOTY3ZWE4NDRmNTk5NzQwNWQzMmFiOTM2OTNfNTY_9e2c4fe7-9b6d-4b72-8470-a2dc0a2f8b9d">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NWZmZTQ0MGIwNGExNDM5M2JlYjAyYWRiYTI3MzI5ZjUvdGFibGVyYW5nZTo1ZmZlNDQwYjA0YTE0MzkzYmViMDJhZGJhMjczMjlmNV82LTAtMS0xLTMwMTU4L3RleHRyZWdpb246N2I0YzZlOTY3ZWE4NDRmNTk5NzQwNWQzMmFiOTM2OTNfNTk_aa1e7a1e-ddaa-42eb-90f1-a7f1965c379f">200-5278</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODI4_3f1d0625-09fa-47e5-9597-bb2bc0659ab5">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODIy_177d571a-fe33-4210-8993-4eb68db46559">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODI0_a7b51c9c-b898-4ea8-b497-0d1c83af7e93">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODI1_0499c772-d303-4c1c-9f03-130700c51d15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NGQ5ZTA5Y2FiMjAyNDc2MWJlYThkMmY1MDM4YzM5Y2UvdGFibGVyYW5nZTo0ZDllMDljYWIyMDI0NzYxYmVhOGQyZjUwMzhjMzljZV8xLTAtMS0xLTMwMTU4_b104ed90-c4af-4fe7-bdaf-dedbce47e5e8">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NGQ5ZTA5Y2FiMjAyNDc2MWJlYThkMmY1MDM4YzM5Y2UvdGFibGVyYW5nZTo0ZDllMDljYWIyMDI0NzYxYmVhOGQyZjUwMzhjMzljZV8xLTEtMS0xLTMwMTU4_a3912d91-526f-4145-9ab9-5508ac2ae002">SLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGFibGU6NGQ5ZTA5Y2FiMjAyNDc2MWJlYThkMmY1MDM4YzM5Y2UvdGFibGVyYW5nZTo0ZDllMDljYWIyMDI0NzYxYmVhOGQyZjUwMzhjMzljZV8xLTItMS0xLTMwMTU4_748a4acc-677c-4b5a-8111-c3cf82033333">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1NWVjYmYyMWYxYTRiY2FhZjc1NGIwYzE0MzcxYzFlL3NlYzplNTVlY2JmMjFmMWE0YmNhYWY3NTRiMGMxNDM3MWMxZV8xL2ZyYWc6NmNlZDljNmEzZDhmNDY1NTlkMjliZmZhMjQ5MmJiYjQvdGV4dHJlZ2lvbjo2Y2VkOWM2YTNkOGY0NjU1OWQyOWJmZmEyNDkyYmJiNF8yODMx_8254a9c0-ada0-4457-a8a4-70389b7bf847">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&1B&^P#>+Y6R;PUW'"[_FS'Z&U!+ P04    "  &@JQ4GZ ;\+$"  #B#
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M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    "  &@JQ4!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  :"K%2NCW*>[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    (  :"K%297)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ !H*L5'@70<=+!   V1   !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    (  :"K%2?H!OPL0(  .(,   -              "  8X,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ !H*L5)>*NQS     $P(   L
M     ( !:@\  %]R96QS+RYR96QS4$L! A0#%     @ !H*L5*K$(A8S 0
M(@(   \              ( !4Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   (  :"K%0D'INBK0   /@!   :              "  ;,1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  :"K%1ED'F2&0$  ,\#
M   3              "  9@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(  .(3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sls-20220512.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="sls-20220512.htm">sls-20220512.htm</File>
    <File>sls-20220512.xsd</File>
    <File>sls-202205128xkexhibit991.htm</File>
    <File>sls-20220512_lab.xml</File>
    <File>sls-20220512_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sls-20220512.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "sls-20220512.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sls-20220512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sls-20220512_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sls-20220512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "sls",
   "nsuri": "http://www.sellaslifesciences.com/20220512",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20220512.htm",
      "contextRef": "ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sellaslifesciences.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20220512.htm",
      "contextRef": "ib8a6948c46a54531911a18e6a2cd5b5f_D20220512-20220512",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001390478-22-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-22-000013-xbrl.zip
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M5\:=G=_,("B+394'R-:K3@"_W C@%QR#>3#\_-M0YC(C)9F6'!/9$>+A0QJ
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M@,B21]-;5Q@:#OBE[>]\&;8!X,%U!N(,HKB)YP_C?I!T8-I@ C(0;91;69W
M"5)DFD4BIB_R(J_G[7%Q??WBGF@7](N(6\U!__H-4V$TT*F!*,RQ:T+/.NW/
M@>@&G+MP &BBDYUA'/.=N</L-0$8:":5,_N0=,!H$)K"86"G@@+RIJ3B!R'S
M<A(1! !R'>05$TR7R_5\6\]8T +=Y,#2GJ">S>L+>ZY NZ!DZ'2ASPQZAL*
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M>&ME>&AI8FET.3DQ+FAT;>T]:U?;2);?]U?4IK,]R5G96'Z!0R;GN(&DF2;
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M!R%\Q0L1L!P@IP^S<]:+0NXRL!@'Q"4.LDL$_.3"R"BSE07,Y *=1:3>D==
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MT%623T?Q9MP%[<6DVL;$78R-G%M8&IO2\%0(3] EX)3WA(G)Q#J4@*%>[8?
M$X)'Z.\MG[Z1>GD4F ET* Y [,/OW .?4NE90L?!0*%VB$1 ;LADS"'W^NF
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M/N;)5H[Q1/:'%D![U7JKD)1Q$"HJQ)@[T[X.FR0;H[X:&!=*\0()-?NA(JU
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M-RKQ:R\H$"]P4;QF/)P470DKE2.5"#LQIL^,<_0DI&B)QBPI,1FE87G:<O+
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M              "  0    !S;',M,C R,C U,3(N:'1M4$L! A0#%     @
M!H*L5*KD&[%P @  B0<  !               ( !IA4  '-L<RTR,#(R,#4Q
M,BYX<V102P$"% ,4    "  &@JQ49VBTF#0B  !-3P$ '0
M@ %$&   <VQS+3(P,C(P-3$R.'AK97AH:6)I=#DY,2YH=&U02P$"% ,4
M"  &@JQ4MBY(4IP*   180  %               @ &S.@  <VQS+3(P,C(P
M-3$R7VQA8BYX;6Q02P$"% ,4    "  &@JQ4*Q#Z@-0&   ),P  %
M        @ &!10  <VQS+3(P,C(P-3$R7W!R92YX;6Q02P4&      4 !0!+
) 0  ATP

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
